BIOMARIN PHARMACEUTICAL INC (BMRN): SEC Filings & AI Analysis
Healthcare. Latest 10-K, 10-Q, and 8-K filings for BIOMARIN PHARMACEUTICAL INC (BMRN) with AI risk scoring and cited answers, grounded in primary-source SEC EDGAR data.
Most recent filing — 10-Q filed November 3, 2026: BEARISH Concern level: HIGH.
Company overview — key questions
Answers are generated from SEC filings and StockHuntr's analysis. Not investment advice.
What is BIOMARIN PHARMACEUTICAL INC (BMRN)?
BIOMARIN PHARMACEUTICAL INC is a publicly traded company in the Healthcare space tracked on StockHuntr, which analyzes its SEC filings (10-K, 10-Q, 8-K) and generates 30-day stock predictions.
What are BMRN's most recent SEC filings?
Recent filings: 10-Q (November 3, 2026), 8-K (November 2, 2026), 8-K (October 6, 2026), 8-K (September 30, 2026), 8-K (September 15, 2026).
What does BMRN's latest filing analysis show?
BMRN's most recent 10-Q (November 3, 2026) is rated BEARISH, concern level HIGH.
What is the 30-day outlook for BMRN?
Based on BMRN's latest filing, the model projects it will perform roughly in line with the S&P 500 over the next 30 days. This is model analysis for research, not investment advice.
Is BMRN a buy?
StockHuntr doesn't issue buy or sell ratings — it's a research tool. For BIOMARIN PHARMACEUTICAL INC (BMRN), its latest 10-Q is rated HIGH concern and the model projects it will perform roughly in line with the S&P 500 over 30 days. Weigh these filing-based signals alongside your own research. This is model analysis for research, not investment advice.
Recent BMRN filings analyzed
Other Healthcare companies
About this analysis
- Primary source:
- View this company's filings on SEC EDGAR
- Additional data:
- Yahoo Finance (market data)
- Method:
- StockHuntr analyzes filings with AI — see our methodology.
- Analysis as of:
- November 3, 2026
- Published by:
- StockHuntr
For research and education only. Nothing here is investment advice.
Loading BMRN snapshot...
Fetching live market data